Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pneumagen Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current prosecution is handled by 1 distinct examiner, D' AMBROSIO, THEA. This examiner is responsible for 1 pending office action, representing the total active workload for the company at this time. Such a focused arrangement allows for direct communication and a clear understanding of the examiner's expectations without the noise of multiple conflicting office actions across different applications.
The administrative scope is narrow, with activity limited to 1 distinct art unit. This centralized structure allows for a consistent prosecution approach, as there is no variation across different art units or examiners. The pending matter dictates the current pace of the portfolio's development within the USPTO. Practitioners can benefit from this lack of complexity by tailoring their arguments to the specific technical standards prevalent in this art unit and the individual examiner's history. This high level of concentration ensures that all legal resources are focused on a singular objective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17905303 | TREATMENT OF VIRAL INFECTION | D' AMBROSIO, THEA | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905303 | TREATMENT OF VIRAL INFECTION | D' AMBROSIO, THEA | 1654 | §102§103§112DPOther | Final Rejection | — | Pending | Aug 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPneumagen Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Thea D' Ambrosio has the most, with 1 of Pneumagen Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
